Horizon Discovery signs Chinese hamster ovary cell deal with LakePharma
16th Sep 2015 15:59
(ShareCast News) - Horizon Discovery Group's bioproduction business has signed a license agreement with LakePharma over the commercial use of a genetically-engineered Chinese Hamster Ovary (CHO) cell line. Horizon's Chief Executive Dr Darrin Disley said the agreement serves as recognition and valida
Read moreHorizon Discovery revenue growth driven by organic gains
20th Jul 2015 09:38
(ShareCast News) - Horizon Discovery posted half year revenue of £8.6m, 112% up on the same period of last year. The AIM listed company said it had strong growth in product and service business revenues, and said it was eligible for further research and development revenues of up to £158 million plu
Read moreHorizon Discovery jumps as company continues to invest
14th Apr 2015 15:17
Biotech group Horizon Discovery Group said annual gross margins and revenue grew strongly in 2014 but investments weighed on profit. The London-listed group said its annual pre-tax loss jumped from £3m to £6.1m on the back of increased research and development costs, while marketing and distribution
Read moreHorizon Discovery awarded £0.8m contract
25th Jul 2014 13:04
Research tools provider Horizon Discovery has been contracted by bio medicine group Otsuka Pharmaceutical Development Commercialisation (OPDC) for $0.8m. The Cambridge-based group has been appointed by Otsuka to perform in vitro cell line screening for clinical stage OPDC development candidates. Th
Read morePremier Foods non-exec makes show of faith
19th Jun 2014 15:58
Pam Powell, a non-executive director of Premier Foods, has acquired 74,369 shares in the group one day after it warned that sales of its key brands were set to fall short of expectations this year. Powell paid 53.5p for each of the shares, spending a total of £39,787. The modest show of faith ca
Read moreNumis Chief reduces stake with sale of 3m shares
11th Jun 2014 15:50
Oliver Hemsley, the Chief Executive Officer of Numis, has traded in three million shares, reducing his stake by almost a quarter to 9.4m. The 270p-a-share disposal generated £8.1m. The sale comes around one month after the group posted a 59% jump in first half revenue at £51.5m. Adjusted pre-t
Read moreHorizon Discovery signs agreement with Genomics
8th May 2014 09:03
Biotechnology group Horizon Discovery has entered into a non-exclusive agreement with science research group ERS Genomics to access the group's gene editing system. The company will be allowed to use technology from DR. Emmanuelle Charpentier and her colleagues for a range of research applications.
Read moreHorizon Discovery discovers warm welcome on AIM debut
27th Mar 2014 10:57
Shares rose in life science research tools supplier Horizon Discovery on its first day of dealings on Thursday. Cambridge-based Horizon, which has been ranked as one of the fastest growing biotechnology companies in Europe by Deloitte, raised a gross £40m as part of its initial public offering at
Read more